Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bexident Aftas Gel
- Development stage
- Phase 3
- Lead developer
- ISDIN
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
Bexident Aftas Gel is a topical oral treatment developed by ISDIN and clinically studied by the University of Milan. It is formulated with hyaluronic acid (sodium hyaluronate) using the proprietary Advanced Hyalurofilm Tech, which creates a protective barrier over oral lesions. The formulation also includes Suprapein®, a protective film former with antibacterial properties. Classified as a CE IIa medical device, the gel is indicated for the treatment of recurrent aphthous stomatitis (canker sores), traumatic oral ulcers (e.g., from orthodontic appliances or dentures), and minor oral wounds. It promotes tissue hydration and regeneration while providing immediate pain relief by shielding nerve endings.
- Brand names
- Bexident Aftas Gel
- Other names
- Bexident Aftas
02
Targets
CD44 (CD44 antigen)
Beyond the preview
Go deeper on Bexident Aftas Gel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bexident Aftas Gel.